SIGA Technologies Key Executives
This section highlights SIGA Technologies's key executives, including their titles and compensation details.
Find Contacts at SIGA Technologies
(Showing 0 of )
SIGA Technologies Earnings
This section highlights SIGA Technologies's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-11 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-11-07 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2024-08-01 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-07 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-03-13 | N/A | N/A |
| Read Transcript | Q3 | 2023 | 2023-11-07 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-08 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-05-04 | N/A | N/A |
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
$5.73
Stock Price
$409.33M
Market Cap
46
Employees
New York, NY
Location
Financial Statements
Access annual & quarterly financial statements for SIGA Technologies, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $138.72M | $139.92M | $110.78M | $133.67M | $124.96M |
| Cost of Revenue | $- | $17.83M | $32.96M | $26.54M | $25.74M |
| Gross Profit | $138.72M | $122.09M | $77.82M | $107.13M | $99.22M |
| Gross Profit Ratio | 100.00% | 87.26% | 70.25% | 80.10% | 79.40% |
| Research and Development Expenses | $5.39M | $16.43M | $24.11M | $9.94M | $10.94M |
| General and Administrative Expenses | $3.84M | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $3.84M | $22.04M | $35.12M | $17.32M | $14.00M |
| Other Expenses | $- | $- | $-24.11M | $710.15K | $719.14K |
| Operating Expenses | $9.23M | $22.04M | $35.12M | $18.03M | $14.72M |
| Cost and Expenses | $9.23M | $56.30M | $68.08M | $44.58M | $40.46M |
| Interest Income | $-6.12M | $4.16M | $- | $101.17K | $2.48M |
| Interest Expense | $- | $- | $- | $- | $3.02M |
| Depreciation and Amortization | $-58.97M | $538.29K | $517.64K | $522.37K | $529.81K |
| EBITDA | $70.52M | $84.16M | $43.22M | $89.62M | $85.03M |
| EBITDA Ratio | 50.84% | 60.15% | 39.48% | 67.12% | 68.47% |
| Operating Income | $129.49M | $83.62M | $42.70M | $89.09M | $84.50M |
| Operating Income Ratio | 93.35% | 59.76% | 38.55% | 66.65% | 67.62% |
| Total Other Income Expenses Net | $-53.42M | $4.16M | $1.43M | $218.94K | $-10.99M |
| Income Before Tax | $76.07M | $87.78M | $44.13M | $89.31M | $73.51M |
| Income Before Tax Ratio | 54.84% | 62.73% | 39.84% | 66.81% | 58.83% |
| Income Tax Expense | $16.86M | $19.71M | $10.23M | $19.86M | $17.17M |
| Net Income | $59.21M | $68.07M | $33.90M | $69.45M | $56.34M |
| Net Income Ratio | 42.69% | 48.65% | 30.61% | 51.96% | 45.09% |
| EPS | $0.83 | $0.95 | $0.46 | $0.92 | $0.71 |
| EPS Diluted | $0.83 | $0.95 | $0.46 | $0.91 | $0.71 |
| Weighted Average Shares Outstanding | 71.25M | 71.36M | 72.93M | 75.32M | 79.26M |
| Weighted Average Shares Outstanding Diluted | 71.77M | 71.68M | 73.55M | 76.40M | 79.44M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $81.47M | $10.01M | $21.81M | $25.43M | $116.48M | $9.24M | $5.88M | $8.32M | $11.36M | $72.21M | $16.67M | $10.54M | $115.36M | $4.85M | $8.65M | $4.81M | $37.73M | $44.26M | $40.35M | $2.62M |
| Cost of Revenue | $17.48M | $1.62M | $12.31M | $3.23M | $14.80M | $4.54M | $6.09M | $6.20M | $7.29M | $9.68M | $7.72M | $8.27M | $17.41M | $3.32M | $3.26M | $2.55M | $7.34M | $7.63M | $7.51M | $3.26M |
| Gross Profit | $63.99M | $8.39M | $9.50M | $22.20M | $101.68M | $4.69M | $-212.41K | $2.13M | $4.07M | $62.53M | $8.94M | $2.27M | $97.95M | $1.53M | $5.39M | $2.26M | $30.39M | $36.63M | $32.84M | $-639.43K |
| Gross Profit Ratio | 78.55% | 83.81% | 43.60% | 87.30% | 87.30% | 50.80% | -3.60% | 25.60% | 35.80% | 86.60% | 53.70% | 21.60% | 84.90% | 31.50% | 62.30% | 47.00% | 80.55% | 82.76% | 81.40% | -24.41% |
| Research and Development Expenses | $- | $1.07M | $2.89M | $3.05M | $2.62M | $1.28M | $4.61M | $2.62M | $16.06M | $6.59M | $6.84M | $3.22M | $2.14M | $2.50M | $1.73M | $1.29M | $7.04M | $2.45M | $1.72M | $2.51M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.39M | $- | $3.87M | $3.18M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $6.91M | $4.82M | $5.53M | $7.88M | $7.38M | $6.00M | $4.43M | $4.24M | $5.88M | $19.66M | $5.87M | $3.52M | $3.75M | $4.31M | $5.22M | $4.06M | $3.39M | $3.57M | $3.87M | $3.18M |
| Other Expenses | $- | $1.96M | $1.32M | $1.50M | $1.19M | $883.15K | $1.19M | $-2.62M | $-16.06M | $-6.59M | $72.37K | $193.26K | $25.12K | $26.25K | $24.23K | $25.57K | $62.86K | $24.93K | $31.93K | $412.36K |
| Operating Expenses | $6.91M | $7.85M | $8.42M | $10.93M | $10.00M | $6.00M | $4.43M | $4.24M | $5.88M | $19.66M | $5.87M | $3.71M | $3.92M | $4.47M | $5.39M | $4.25M | $3.59M | $3.73M | $4.05M | $3.36M |
| Cost and Expenses | $24.38M | $9.47M | $20.73M | $14.15M | $24.80M | $10.54M | $10.52M | $10.43M | $13.16M | $29.34M | $13.60M | $11.98M | $21.33M | $7.79M | $8.65M | $6.80M | $10.93M | $11.36M | $11.55M | $6.62M |
| Interest Income | $- | $- | $- | $- | $1.19M | $883.15K | $1.19M | $- | $677.23K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $890.63K | $- | $- | $- | $755.33K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.02M |
| Depreciation and Amortization | $130.73K | $- | $140.84K | $138.47K | $137.59K | $135.92K | $133.66K | $131.12K | $131.20K | $130.20K | $128.71K | $127.53K | $128.70K | $128.83K | $134.01K | $130.83K | $132.68K | $129.47K | $134.51K | $133.16K |
| EBITDA | $57.22M | $542.09K | $1.22M | $11.41M | $91.81M | $-1.17M | $-4.50M | $-1.98M | $-996.26K | $43.00M | $3.07M | $-1.31M | $94.15M | $-2.82M | $135.11K | $-1.86M | $26.94M | $33.03M | $28.93M | $-8.45M |
| EBITDA Ratio | 70.23% | 5.42% | 5.60% | 44.88% | 78.82% | -12.70% | -78.91% | -23.76% | -2.12% | 59.55% | 18.90% | -15.77% | 81.64% | -57.55% | 1.84% | -38.08% | 71.56% | 74.68% | 71.78% | -131.79% |
| Operating Income | $57.09M | $542.09K | $1.08M | $11.28M | $91.68M | $-1.31M | $-4.64M | $-2.11M | $-1.80M | $42.87M | $3.07M | $-1.44M | $94.02M | $-2.94M | $1.10K | $-1.99M | $26.80M | $32.90M | $28.80M | $-4.00M |
| Operating Income Ratio | 70.07% | 5.42% | 4.95% | 44.34% | 78.71% | -14.18% | -78.91% | -25.33% | -15.89% | 59.37% | 18.42% | -13.65% | 81.51% | -60.75% | 0.01% | -41.33% | 71.04% | 74.33% | 71.37% | -152.61% |
| Total Other Income Expenses Net | $1.50M | $1.33M | $1.32M | $1.94M | $1.19M | $883.15K | $1.19M | $890.63K | $677.23K | $258.98K | $121.93K | $374.43K | $-151.66K | $-1.04M | $466.50K | $944.37K | $-553.18K | $-1.25M | $-1.59M | $-7.60M |
| Income Before Tax | $58.58M | $1.87M | $2.40M | $13.22M | $92.87M | $-426.10K | $-3.45M | $-1.22M | $-1.13M | $43.13M | $3.19M | $-1.06M | $93.87M | $-3.98M | $467.61K | $-1.05M | $26.25M | $31.65M | $27.21M | $-11.60M |
| Income Before Tax Ratio | 71.91% | 18.71% | 10.99% | 51.98% | 79.73% | -4.61% | -58.65% | -14.63% | -9.93% | 59.73% | 19.16% | -10.10% | 81.38% | -82.21% | 5.40% | -21.71% | 69.57% | 71.50% | 67.44% | -442.79% |
| Income Tax Expense | $12.82M | $528.65K | $565.22K | $2.94M | $20.61M | $-33.03K | $-572.19K | $-299.42K | $-315.67K | $10.09M | $1.16M | $-703.41K | $20.67M | $-870.80K | $298.41K | $-232.93K | $6.09M | $7.46M | $6.32M | $-2.70M |
| Net Income | $45.76M | $1.34M | $1.83M | $10.28M | $72.26M | $-393.07K | $-2.88M | $-918.25K | $-811.79K | $33.04M | $2.04M | $-361.05K | $73.21M | $-3.11M | $169.20K | $-812.11K | $20.16M | $24.19M | $20.89M | $-8.90M |
| Net Income Ratio | 56.17% | 13.43% | 8.40% | 40.41% | 62.03% | -4.26% | -48.92% | -11.03% | -7.15% | 45.76% | 12.22% | -3.43% | 63.46% | -64.24% | 1.96% | -16.87% | 53.44% | 54.65% | 51.77% | -339.63% |
| EPS | $0.64 | $0.02 | $0.03 | $0.14 | $1.02 | $-0.01 | $-0.04 | $-0.01 | $-0.01 | $0.45 | $0.03 | $0.00 | $0.98 | $-0.04 | $0.00 | $-0.01 | $0.26 | $0.31 | $0.26 | $-0.11 |
| EPS Diluted | $0.64 | $0.02 | $0.03 | $0.14 | $1.02 | $-0.01 | $-0.04 | $-0.01 | $-0.01 | $0.45 | $0.03 | $0.00 | $0.98 | $-0.04 | $0.00 | $-0.01 | $0.26 | $0.31 | $0.26 | $-0.11 |
| Weighted Average Shares Outstanding | 71.25M | 71.37M | 71.15M | 71.09M | 71.09M | 71.08M | 71.09M | 72.20M | 72.70M | 73.02M | 72.68M | 73.07M | 73.82M | 74.84M | 75.81M | 76.76M | 77.39M | 78.08M | 80.34M | 80.89M |
| Weighted Average Shares Outstanding Diluted | 71.77M | 71.77M | 71.75M | 71.56M | 71.09M | 71.08M | 71.09M | 72.20M | 72.70M | 73.26M | 73.33M | 73.88M | 74.84M | 74.84M | 76.66M | 77.57M | 78.08M | 78.17M | 80.52M | 81.24M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $155.40M | $150.15M | $98.79M | $103.14M | $117.89M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $155.40M | $150.15M | $98.79M | $103.14M | $117.89M |
| Net Receivables | $21.17M | $21.13M | $45.41M | $83.65M | $3.34M |
| Inventory | $49.56M | $64.22M | $39.27M | $19.51M | $20.27M |
| Other Current Assets | $4.91M | $3.50M | $2.32M | $2.45M | $2.11M |
| Total Current Assets | $231.04M | $238.99M | $185.79M | $208.75M | $143.61M |
| Property Plant Equipment Net | $1.30M | $1.33M | $1.85M | $2.37M | $2.10M |
| Goodwill | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $10.85M | $11.05M | $6.25M | $2.42M | $2.54M |
| Other Non-Current Assets | $240.68K | $2.08M | $252.55K | $286.58K | $676.92K |
| Total Non-Current Assets | $13.29M | $15.36M | $9.25M | $5.97M | $6.22M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $244.34M | $254.35M | $195.04M | $214.73M | $149.83M |
| Account Payables | $1.34M | $1.46M | $3.36M | $2.03M | $1.28M |
| Short Term Debt | $- | $564.01K | $528.17K | $466.83K | $449.94K |
| Tax Payables | $8.02M | $21.69M | $1.31M | $19.21M | $919.55K |
| Deferred Revenue | $10.33M | $20.79M | $10.58M | $3.76M | $3.28M |
| Other Current Liabilities | $5.64M | $9.62M | $16.32M | $5.02M | $4.55M |
| Total Current Liabilities | $25.33M | $54.12M | $21.52M | $30.49M | $10.48M |
| Long Term Debt | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $536.05K | $645.46K | $578.76K |
| Other Non-Current Liabilities | $3.20M | $3.38M | $3.36M | $9.92M | $9.55M |
| Total Non-Current Liabilities | $3.20M | $3.38M | $3.36M | $9.92M | $9.55M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $28.53M | $57.49M | $24.88M | $40.41M | $20.04M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $7.14K | $7.11K | $7.27K | $7.35K | $7.72K |
| Retained Earnings | $-22.84M | $-38.94M | $-63.80M | $-51.76M | $-95.19M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $0 | $-0 | $- |
| Other Total Stockholders Equity | $238.64M | $235.80M | $233.96M | $226.07M | $224.98M |
| Total Stockholders Equity | $215.80M | $196.86M | $170.16M | $174.31M | $129.79M |
| Total Equity | $215.80M | $196.86M | $170.16M | $174.31M | $129.79M |
| Total Liabilities and Stockholders Equity | $244.34M | $254.35M | $195.04M | $214.73M | $149.83M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $244.34M | $254.35M | $195.04M | $214.73M | $149.83M |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $546.82K | $564.01K | $528.17K | $466.83K | $449.94K |
| Net Debt | $-155.40M | $-149.58M | $-98.26M | $-102.67M | $-117.44M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $155.40M | $99.27M | $106.95M | $143.87M | $150.15M | $71.11M | $76.21M | $115.68M | $98.79M | $109.75M | $114.53M | $153.26M | $103.14M | $92.82M | $98.49M | $106.53M | $117.89M | $78.66M | $53.07M | $77.38M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $155.40M | $99.27M | $106.95M | $143.87M | $150.15M | $71.11M | $76.21M | $115.68M | $98.79M | $109.75M | $114.53M | $153.26M | $103.14M | $92.82M | $98.49M | $106.53M | $117.89M | $78.66M | $53.07M | $77.38M |
| Net Receivables | $21.17M | $12.09M | $8.95M | $18.13M | $21.13M | $8.05M | $6.03M | $12.32M | $45.41M | $54.93M | $19.60M | $5.34M | $83.65M | $3.82M | $7.21M | $4.00M | $3.34M | $40.40M | $36.61M | $1.69M |
| Inventory | $49.56M | $62.02M | $55.66M | $63.72M | $64.22M | $64.95M | $50.50M | $42.58M | $39.27M | $31.26M | $16.43M | $16.28M | $19.51M | $29.67M | $19.60M | $20.41M | $20.27M | $10.75M | $14.01M | $16.34M |
| Other Current Assets | $4.91M | $7.30M | $4.91M | $2.17M | $3.50M | $1.86M | $1.56M | $3.92M | $2.32M | $1.93M | $6.17M | $4.47M | $2.45M | $5.24M | $3.55M | $3.90M | $2.11M | $2.58M | $2.76M | $5.24M |
| Total Current Assets | $231.04M | $180.69M | $176.48M | $227.89M | $238.99M | $145.97M | $134.30M | $172.53M | $185.79M | $196.90M | $153.64M | $177.11M | $208.75M | $128.94M | $127.07M | $132.89M | $143.61M | $131.10M | $105.07M | $98.02M |
| Property Plant Equipment Net | $1.30M | $1.41M | $1.52M | $1.19M | $1.33M | $1.47M | $1.61M | $1.72M | $1.85M | $1.98M | $2.11M | $2.24M | $2.37M | $2.47M | $2.60M | $1.99M | $2.10M | $2.24M | $2.37M | $2.50M |
| Goodwill | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K | $898.33K |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $10.85M | $12.10M | $11.61M | $11.01M | $11.53M | $7.90M | $7.59M | $6.73M | $6.25M | $4.18M | $3.04M | $4.04M | $2.42M | $2.95M | $2.73M | $2.57M | $2.54M | $6.48M | $11.18M | $16.30M |
| Other Non-Current Assets | $240.68K | $253.60K | $2.16M | $2.15M | $2.08M | $2.14M | $2.12M | $2.04M | $252.55K | $261.81K | $249.17K | $265.43K | $286.58K | $306.72K | $392.67K | $419.45K | $676.92K | $702.88K | $901.91K | $847.98K |
| Total Non-Current Assets | $13.29M | $14.67M | $16.18M | $15.25M | $15.85M | $12.41M | $12.21M | $11.39M | $9.25M | $7.32M | $6.30M | $7.44M | $5.97M | $6.63M | $6.62M | $5.88M | $6.22M | $10.32M | $15.35M | $20.55M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $244.34M | $195.35M | $192.66M | $243.15M | $254.84M | $158.38M | $146.51M | $183.92M | $195.04M | $204.22M | $159.94M | $184.55M | $214.73M | $135.56M | $133.69M | $138.77M | $149.83M | $141.42M | $120.42M | $118.57M |
| Account Payables | $1.34M | $1.26M | $1.03M | $2.52M | $1.46M | $564.27K | $1.08M | $1.14M | $3.36M | $2.45M | $1.21M | $1.78M | $2.03M | $9.96M | $675.40K | $446.80K | $1.28M | $1.12M | $630.16K | $4.77M |
| Short Term Debt | $546.82K | $535.23K | $523.89K | $503.47K | $564.01K | $554.73K | $545.56K | $536.63K | $528.17K | $519.20K | $507.14K | $486.75K | $466.83K | $496.68K | $433.44K | $393.94K | $449.94K | $441.99K | $434.13K | $427.06K |
| Tax Payables | $8.02M | $127.81K | $82.46K | $2.70M | $21.69M | $54.43K | $11.82K | $1.34M | $1.31M | $9.12M | $634.62K | $808.77K | $19.21M | $48.26K | $27.41K | $697.84K | $919.55K | $3.71M | $- | $- |
| Deferred Revenue | $10.33M | $13.73M | $13.73M | $20.79M | $20.79M | $21.90M | $11.37M | $10.52M | $10.58M | $10.13M | $7.04M | $793.46K | $3.76M | $3.59M | $3.65M | $3.57M | $3.28M | $6.64M | $10.63M | $13.60M |
| Other Current Liabilities | $5.09M | $6.65M | $6.01M | $48.29M | $9.62M | $7.67M | $5.97M | $4.94M | $16.32M | $5.24M | $7.30M | $3.37M | $5.02M | $4.85M | $3.18M | $2.40M | $4.55M | $4.40M | $3.87M | $2.63M |
| Total Current Liabilities | $25.33M | $22.30M | $21.38M | $74.81M | $54.12M | $30.74M | $18.99M | $18.48M | $21.52M | $27.46M | $16.69M | $7.24M | $30.49M | $18.94M | $7.97M | $7.51M | $10.48M | $16.30M | $15.56M | $21.42M |
| Long Term Debt | $- | $- | $- | $- | $335.99K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $-335.99K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $483.34K | $- | $- | $- | $536.05K | $- | $- | $- | $645.46K | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $3.20M | $3.61M | $3.72M | $3.34M | $3.04M | $3.50M | $3.45M | $3.35M | $3.36M | $3.63M | $3.48M | $9.57M | $9.92M | $10.07M | $8.99M | $8.57M | $9.55M | $12.16M | $10.72M | $9.01M |
| Total Non-Current Liabilities | $3.20M | $3.61M | $3.72M | $3.34M | $3.86M | $3.50M | $3.45M | $3.35M | $3.36M | $3.63M | $3.48M | $9.57M | $9.92M | $10.07M | $8.99M | $8.57M | $9.55M | $12.16M | $10.72M | $9.01M |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $28.53M | $25.91M | $25.10M | $78.16M | $57.98M | $34.24M | $22.44M | $21.83M | $24.88M | $31.09M | $20.17M | $16.81M | $40.41M | $29.01M | $16.97M | $16.08M | $20.04M | $28.46M | $26.28M | $30.43M |
| Preferred Stock | $- | $- | $- | $- | $0 | $0 | $0 | $0 | $- | $0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $7.14K | $7.14K | $7.13K | $7.11K | $7.11K | $7.11K | $7.11K | $7.15K | $7.27K | $7.30K | $7.30K | $7.26K | $7.35K | $7.43K | $7.54K | $7.62K | $7.72K | $7.78K | $7.86K | $8.11K |
| Retained Earnings | $-22.84M | $-68.60M | $-69.95M | $-71.78M | $-38.94M | $-111.20M | $-110.81M | $-72.28M | $-63.80M | $-60.14M | $-93.18M | $-58.70M | $-51.76M | $-119.21M | $-108.97M | $-102.53M | $-95.19M | $-108.63M | $-127.26M | $-132.92M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $-0 | $-0 | $-0 | $-0 | $0 | $-0 | $-0 | $- | $-0 | $- | $- | $-4.23M | $- | $-4.12M | $-3.99M | $-3.86M |
| Other Total Stockholders Equity | $238.64M | $238.03M | $237.50M | $236.77M | $235.80M | $235.33M | $234.87M | $234.37M | $233.96M | $233.27M | $232.94M | $226.43M | $226.07M | $225.76M | $225.68M | $225.21M | $224.98M | $221.59M | $221.38M | $221.06M |
| Total Stockholders Equity | $215.80M | $169.44M | $167.56M | $164.99M | $196.86M | $124.14M | $124.07M | $162.09M | $170.16M | $173.14M | $139.77M | $167.74M | $174.31M | $106.56M | $116.72M | $122.68M | $129.79M | $112.96M | $94.13M | $88.14M |
| Total Equity | $215.80M | $169.44M | $167.56M | $164.99M | $196.86M | $124.14M | $124.07M | $162.09M | $170.16M | $173.14M | $139.77M | $167.74M | $174.31M | $106.56M | $116.72M | $122.68M | $129.79M | $112.96M | $94.13M | $88.14M |
| Total Liabilities and Stockholders Equity | $244.34M | $195.35M | $192.66M | $243.15M | $254.84M | $158.38M | $146.51M | $183.92M | $195.04M | $204.22M | $159.94M | $184.55M | $214.73M | $135.56M | $133.69M | $138.77M | $149.83M | $141.42M | $120.42M | $118.57M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $244.34M | $195.35M | $192.66M | $243.15M | $254.84M | $158.38M | $146.51M | $183.92M | $195.04M | $204.22M | $159.94M | $184.55M | $214.73M | $135.56M | $133.69M | $138.77M | $149.83M | $141.42M | $120.42M | $118.57M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $546.82K | $535.23K | $1.62M | $1.30M | $1.46M | $554.73K | $545.56K | $536.63K | $528.17K | $519.20K | $507.14K | $486.75K | $466.83K | $496.68K | $433.44K | $393.94K | $449.94K | $441.99K | $434.13K | $427.06K |
| Net Debt | $-154.85M | $-98.73M | $-105.33M | $-142.57M | $-148.68M | $-70.56M | $-75.67M | $-115.14M | $-98.26M | $-109.23M | $-114.02M | $-152.77M | $-102.67M | $-92.32M | $-98.05M | $-106.13M | $-117.44M | $-78.22M | $-52.63M | $-76.95M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $59.21M | $68.07M | $33.90M | $69.45M | $56.34M |
| Depreciation and Amortization | $538.42K | $538.29K | $517.64K | $522.37K | $529.81K |
| Deferred Income Tax | $193.42K | $-4.80M | $-3.83M | $121.45K | $11.61M |
| Stock Based Compensation | $3.64M | $2.05M | $1.78M | $1.27M | $1.35M |
| Change in Working Capital | $-4.69M | $28.36M | $9.44M | $-60.37M | $-7.70M |
| Accounts Receivables | $-35.18K | $24.28M | $38.24M | $-80.31M | $827.73K |
| Inventory | $327.37K | $-25.52M | $-19.96M | $136.37K | $-8.01M |
| Accounts Payables | $-5.74M | $2.00M | $2.07M | $986.87K | $-2.20M |
| Other Working Capital | $753.44K | $27.61M | $-10.91M | $18.82M | $1.68M |
| Other Non Cash Items | $-10.13M | $579.24K | $-199.19K | $501.00K | $9.39M |
| Net Cash Provided by Operating Activities | $48.76M | $94.80M | $41.61M | $11.49M | $71.52M |
| Investments in Property Plant and Equipment | $-42.45K | $-21.69K | $- | $-50.62K | $-15.50K |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-42.45K | $-21.69K | $- | $-50.62K | $-15.50K |
| Debt Repayment | $- | $- | $- | $- | $-85.91M |
| Common Stock Issued | $417.00K | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $-11.07M | $-13.01M | $-26.02M | $-28.50M |
| Dividends Paid | $-42.67M | $-32.14M | $-32.94M | $- | $- |
| Other Financing Activities | $-799.89K | $-214.79K | $-12.53K | $-173.92K | $-184.02K |
| Net Cash Used Provided by Financing Activities | $-43.46M | $-43.42M | $-45.96M | $-26.20M | $-114.60M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $5.25M | $51.36M | $-4.35M | $-14.75M | $-43.10M |
| Cash at End of Period | $155.40M | $150.15M | $98.79M | $103.14M | $117.89M |
| Cash at Beginning of Period | $150.15M | $98.79M | $103.14M | $117.89M | $160.99M |
| Operating Cash Flow | $48.76M | $94.80M | $41.61M | $11.49M | $71.52M |
| Capital Expenditure | $-42.45K | $-21.69K | $- | $-50.62K | $-15.50K |
| Free Cash Flow | $48.72M | $94.78M | $41.61M | $11.44M | $71.50M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $45.76M | $1.34M | $1.83M | $10.28M | $72.26M | $-393.07K | $-2.88M | $-918.25K | $-811.79K | $33.04M | $2.04M | $-361.05K | $73.21M | $-3.11M | $169.20K | $-812.11K | $20.16M | $24.19M | $20.89M | $-8.90M |
| Depreciation and Amortization | $130.73K | $128.38K | $140.84K | $138.47K | $137.59K | $135.92K | $133.66K | $131.12K | $131.20K | $130.20K | $128.71K | $127.53K | $128.70K | $128.83K | $134.01K | $130.83K | $132.68K | $129.47K | $134.51K | $133.16K |
| Deferred Income Tax | $- | $- | $-600.26K | $36.45K | $-3.15M | $-305.83K | $-857.93K | $-483.43K | $-3.21M | $-1.14M | $995.33K | $-1.61M | $529.68K | $1.07M | $-158.88K | $-28.54K | $3.94M | $2 | $- | $-2.15M |
| Stock Based Compensation | $764.07K | $813.77K | $932.29K | $1.13M | $462.47K | $459.82K | $721.44K | $408.73K | $686.42K | $328.69K | $395.45K | $368.75K | $308.49K | $243.50K | $467.40K | $246.41K | $387.58K | $380.82K | $323.53K | $259.02K |
| Change in Working Capital | $19.92M | $7.32M | $10.38M | $-17.70M | $9.31M | $-5.04M | $-736.96K | $24.83M | $-4.32M | $-38.29M | $-4.12M | $56.79M | $-57.91M | $3.39M | $-2.39M | $-3.45M | $13.04M | $5.37M | $-32.06M | $5.94M |
| Accounts Receivables | $-9.08M | $-3.13M | $9.17M | $3.00M | $-13.08M | $-2.02M | $6.29M | $33.09M | $9.52M | $-35.33M | $-14.26M | $78.31M | $-79.83M | $3.38M | $-3.20M | $-661.00K | $37.06M | $-3.79M | $-34.93M | $2.48M |
| Inventory | $12.67M | $-8.71M | $7.52M | $1.51M | $715.59K | $-14.50M | $-8.44M | $-3.30M | $-8.04M | $-14.84M | $-176.15K | $3.10M | $10.09M | $-9.99M | $179.77K | $-144.85K | $-9.52M | $3.26M | $2.34M | $-4.09M |
| Accounts Payables | $-2.08M | $766.72K | $-957.80K | $-3.47M | $2.70M | $1.23M | $1.08M | $-3.01M | $1.15M | $-668.54K | $3.46M | $-1.88M | $-7.24M | $11.04M | $510.94K | $-3.33M | $-2.68M | $4.90M | $-2.80M | $-1.62M |
| Other Working Capital | $18.41M | $18.40M | $-5.36M | $-18.75M | $18.98M | $10.25M | $335.11K | $-1.95M | $-6.94M | $12.55M | $7.85M | $-22.74M | $19.06M | $-1.05M | $124.84K | $683.45K | $-11.82M | $997.84K | $3.33M | $9.17M |
| Other Non Cash Items | $-10.26M | $-16.99M | $-21.26M | $359.75K | $16.30K | $44.39K | $35.13K | $483.43K | $-584.18K | $1.15M | $10.50M | $1.40M | $368.44K | $-82.16K | $188.44K | $-890.26K | $8.28M | $1.27M | $1.62M | $8.04M |
| Net Cash Provided by Operating Activities | $56.31M | $-7.38M | $5.95M | $-6.12M | $79.03M | $-5.10M | $-3.58M | $24.45M | $-8.11M | $-4.78M | $-2.21M | $56.71M | $16.10M | $1.63M | $-1.43M | $-4.81M | $45.95M | $31.34M | $-9.09M | $3.32M |
| Investments in Property Plant and Equipment | $-17.84K | $-22.43K | $-2.19K | $- | $21.69K | $- | $-21.69K | $- | $- | $- | $- | $- | $-26.20K | $- | $-10.70K | $-13.72K | $15.50K | $- | $- | $-15.50K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $-2.19K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $24.42K | $- | $- | $- | $15.50K | $- | $- | $- |
| Net Cash Used for Investing Activities | $-17.84K | $-22.43K | $-2.19K | $- | $21.69K | $- | $-21.69K | $- | $- | $- | $- | $- | $-26.20K | $- | $-10.70K | $-13.72K | $15.50K | $- | $- | $-15.50K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-85.91M |
| Common Stock Issued | $- | $- | $- | $417.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $355.54K | $-196.56K | $-158.98K | $11.07M | $- | $-3.52M | $-7.56M | $-2.86M | $- | $-3.58M | $-6.57M | $-5.76M | $-7.13M | $-6.60M | $-6.53M | $-6.72M | $-5.57M | $-15.22M | $-993.38K |
| Dividends Paid | $- | $8.47K | $-42.67M | $- | $-32.14M | $-32.14M | $-32.14M | $- | $-3.92K | $- | $-32.94M | $- | $- | $- | $- | $- | $-89.73M | $- | $- | $- |
| Other Financing Activities | $-161.76K | $-282.60K | $-196.56K | $-158.98K | $75.56M | $32.14M | $-214.79K | $- | $- | $- | $- | $-12.53K | $- | $-160.56K | $- | $-13.36K | $-7 | $-174.26K | $- | $-9.75K |
| Net Cash Used Provided by Financing Activities | $-161.76K | $-274.13K | $-42.87M | $-158.98K | $43.42M | $- | $-35.87M | $-7.56M | $-2.85M | $- | $-36.52M | $-6.59M | $-5.76M | $-7.30M | $-6.60M | $-6.54M | $-6.72M | $-5.74M | $-15.22M | $-86.92M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-15.50K | $- | $- | $- |
| Net Change in Cash | $56.13M | $-7.68M | $-36.92M | $-6.28M | $79.03M | $-5.10M | $-39.47M | $16.89M | $-10.96M | $-4.78M | $-38.73M | $50.12M | $10.32M | $-5.67M | $-8.04M | $-11.36M | $39.23M | $25.60M | $-24.31M | $-83.61M |
| Cash at End of Period | $155.40M | $99.27M | $106.95M | $143.87M | $150.15M | $71.11M | $76.21M | $115.68M | $98.79M | $109.75M | $114.53M | $153.26M | $103.14M | $92.82M | $98.49M | $106.53M | $117.89M | $78.66M | $53.07M | $77.38M |
| Cash at Beginning of Period | $99.27M | $106.95M | $143.87M | $150.15M | $71.11M | $76.21M | $115.68M | $98.79M | $109.75M | $114.53M | $153.26M | $103.14M | $92.82M | $98.49M | $106.53M | $117.89M | $78.66M | $53.07M | $77.38M | $160.99M |
| Operating Cash Flow | $56.31M | $-7.38M | $5.95M | $-6.12M | $79.03M | $-5.10M | $-3.58M | $24.45M | $-8.11M | $-4.78M | $-2.21M | $56.71M | $16.10M | $1.63M | $-1.43M | $-4.81M | $45.95M | $31.34M | $-9.09M | $3.32M |
| Capital Expenditure | $-17.84K | $-22.43K | $-2.19K | $- | $21.69K | $- | $-21.69K | $- | $- | $- | $- | $- | $-26.20K | $- | $-10.70K | $-13.72K | $15.50K | $- | $- | $-15.50K |
| Free Cash Flow | $56.29M | $-7.41M | $5.95M | $-6.12M | $79.05M | $-5.10M | $-3.60M | $24.45M | $-8.11M | $-4.78M | $-2.21M | $56.71M | $16.08M | $1.63M | $-1.44M | $-4.82M | $45.96M | $31.34M | $-9.09M | $3.31M |
SIGA Technologies Dividends
Explore SIGA Technologies's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
9.96%
Dividend Payout Ratio
72.05%
Dividend Paid & Capex Coverage Ratio
1.14x
SIGA Technologies Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.6 | $0.6 | March 25, 2024 | March 26, 2024 | April 11, 2024 | March 12, 2024 |
| $0.45 | $0.45 | May 15, 2023 | May 16, 2023 | June 01, 2023 | May 14, 2023 |
| $0.45 | $0.45 | May 16, 2022 | May 17, 2022 | June 02, 2022 | May 05, 2022 |
SIGA Technologies News
Read the latest news about SIGA Technologies, including recent articles, headlines, and updates.
SIGA Appoints Retired General John M. Keane to its Board of Directors
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army General John “Jack” Keane to its Board of Directors, effective immediately. General Keane, a retired four-star general, completed 37 years of public service in December 2003, culminating with his appointment as acting Chief of Staff and Vice Chief of Staff of the U.S. Army from 1999 to 2003.
SIGA Technologies, Inc. (SIGA) Q4 2024 Earnings Call Transcript
SIGA Technologies, Inc. (NASDAQ:SIGA ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Diem Nguyen - Chief Executive Officer Dan Luckshire - Executive Vice President and Chief Financial Officer Conference Call Participants Jyoti Prakash - Edison Group Brian Adams - Carter, Terry & Company Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements majoring this call are based on management's current expectations and observations, and are subject to risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2024.
SIGA to Host Business Update Call on March 11, 2025 Following Release of Fourth-Quarter and Full Year 2024 Financial Results
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 11, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, a commercial stage pharmaceutical company, announced today that its antiviral treatment TEPOXX (tecovirimat 200 mg capsules), marketed as TPOXX in the United States, has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as well as complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg. TEPOXX is the first antiviral therapy approved by the Pharmaceuticals and Medical Devices Agency (PMDA), in collaboration with the Japan Ministry of Health, Labour and Welfare, for the treatment of orthopoxviruses.
Are Investors Undervaluing Siga Technologies (SIGA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced results from an interim analysis of the Study of Tecovirimat for Human Mpox Virus (STOMP) clinical trial (NCT05534984). NIAID reported that SIGA's tecovirimat, a highly targeted antiviral treatment, did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo in patients with mild to moderate clade II mpox. Based on this and additional analyses, the study Data Safety and Monitoring Board (DSMB) recommended to stop enrolling patients in the randomized arms of the study. NIAID accepted this recommendation and subsequently decided to take a similar action in the open label arm of this study, which included severe and at-risk of developing severe disease patients. Data analysis is not yet complete for primary endpoint subgroups and detailed secondary and exploratory endpoints.
Should Value Investors Buy Siga Technologies (SIGA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Siga Technologies (SIGA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Siga Technologies (SIGA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook
SIGA Technologies, Inc.'s reliance on TPOXX, coupled with mixed clinical trial results, and the need to renew the contract with the U.S. in 2025, shed doubts about Siga's long-term outlook. Emergent BioSolutions Inc.'s diversified product portfolio and turnaround strategy under new CEO Joseph Papa provides an optimistic long-term outlook. Siga's financial stability is threatened by potential policy changes driven by the new U.S. government and TPOXX's uncertain efficacy against mpox.
SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket
SIGA Technologies' stock has declined 37% since my "speculative buy" recommendation in August, driven by a muted response to the mpox outbreak. The initial recommendation was based on the WHO's mpox emergency declaration and potential increased demand for SIGA's lead asset, tecovirimat. The mpox outbreak has waned, and global authorities' response has been less aggressive, leading to lower-than-expected demand for tecovirimat.
SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman
SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox.
SIGA Technologies, Inc. (SIGA) Q3 2024 Earnings Call Transcript
SIGA Technologies, Inc. (NASDAQ:SIGA ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Diem Nguyen - CEO Dan Luckshire - CFO Conference Call Participants Jyoti Prakash - Edison Group Operator Good afternoon, ladies and gentlemen, and welcome to the SIGA Technologies Third Quarter 2024 Earnings Call. At this time, all lines are in a listen-only mode.
SIGA Technologies, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SIGA
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.
SIGA Technologies, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SIGA
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.
SIGA Technologies, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- SIGA
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for SIGA.